Applied DNA Sciences Announces Resignations and Appointment of New Directors
News Mar 24, 2006
Applied DNA Sciences, Inc. (APDN) has announced that Peter Brocklesby resigned his position as a director and President of APDN and APDN (B.V.I.) Inc., its wholly owned subsidiary, and Lawrence Lee resigned his position as a director and Chief Technology Strategist of APDN, effective March 22, 2006, to pursue other interests.
APDN also announced that Dr. James A. Hayward, Chief Executive Officer, and Dr. Sanford R. Simon have been appointed to the Board of Directors of APDN, effective March 17, 2006.
Dr. James Hayward has been acting Chief Executive Officer since October 5, 2005. Since June 2004, Dr. Hayward has been the Chairman of Evotope Biosciences, Inc.
Since 2001, Dr. Hayward has been a director of Q-RNA, Inc. Since 2000, Dr. Hayward has been a General Partner of Double D Venture Fund, a venture capital firm based in New York, New York.
Between 1990 and July 2004, Dr. Hayward was the Chairman, President and CEO of The Collaborative Group, Ltd., a provider of products and services to the biotechnology, pharmaceutical and consumer-product industries based in Stony Brook, New York.
Dr. Hayward received his bachelor's degree in Biology and Chemistry from the State University of New York at Oneonta in 1976, his Ph.D. in Molecular Biology from the State University of New York at Stony Brook in 1983, and an honorary Doctor of Science from Stony Brook in 2000.
Dr. Hayward has served on the boards of the Council on Biotechnology, the Long Island Association, the Stony Brook Foundation, The Research Foundation of State University of New York Board of Directors, New York Biotechnology Association and the Long Island Life Sciences Initiative.
"We believe the collective expertise in the biotechnology, pharmaceutical, and consumer product industries of our new board members adds comprehensive depth to our board of directors that will serve us well as we continue to advance through this important stage of development," said James A. Hayward, CEO of APDN.
"We also believe it is critical for the company to have excellent relations with the biotechnology industry, the university and the government to ensure that we are well-positioned to achieve our development goals."
Dr. Sanford R. Simon has over 40 years' experience in biochemistry and cell biology as well as applied genetic research. He has been a Professor of Biochemistry, Cell Biology and Pathology at Stony Brook since 1997.
He joined the faculty at Stony Brook as an Assistant Professor in 1969 and was promoted to Associate Professor with tenure in 1975. Dr. Simon was a member of the Board of Directors of The Collaborative Group from 1995 to 2004.
From 1967 to 1969 Dr. Simon was a Guest Investigator at Rockefeller University. Dr. Simon received a B.A. in Zoology and Chemistry from Columbia University in 1963, a Ph.D. in Biochemistry from Rockefeller University in 1967, and studied as a postdoctoral fellow with Nobel Prize winner Max Perutz in Cambridge, England.
Dr. Simon's research efforts, which currently include development of vaccines and small molecule therapeutics for biodefense applications, have been funded over the past several years in part by grants from the National Institutes of Health and the Department of Defense.
Dr. Simon is also the principal investigator on a project entitled "A Chimeric Method and System for DNA Encryption and Authentication", funded jointly by APDN, Stony Brook's Center for Biotechnology and the New York State Office of Science, Technology and Academic Research.
Dr. Simon stated, "I am very pleased to be able to contribute to the direction of this company, and I look forward to offering my background in biochemistry and cell biology as a resource for the Board and management team of APDN."
DNA Methylation Related to Liver Disease in Obese PatientsNews
DNA methylation implicated in initiation of liver fibrosis in non-alcoholic fatty liver diseaseREAD MORE
UCL Technology Fund Investment MeiraGTx Raises $75 Million in IPONews
MeiraGTx Holdings plc raised $75 million of gross proceeds upon close of the company’s initial public offering (IPO).READ MORE
International Conference on Neurooncology and Neurosurgery
Sep 17 - Sep 18, 2018